| Project/Area Number |
25293306
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
Namba Hiroki 浜松医科大学, 医学部, 教授 (60198405)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
天野 慎士 浜松医科大学, 医学部, 特任研究員 (70464138)
徳山 勤 浜松医科大学, 医学部附属病院, 講師 (90313957)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
DEZAWA MARI 東北大学, 医学部, 教授 (50272323)
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
|
|---|
| Keywords | glioma / gene therapy / stem cells / bystander effect / migration / viral thymidine kinase / ganciclovir / 遺伝子治療 / 悪性グリオーマ / 多能性幹細胞 / ガンシクロビル / チミジンキナーゼ / 遊走能 |
|---|
| Outline of Final Research Achievements |
Suicide gene therapy based on the herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) is an efficient strategy for treating malignant gliomas. In the present study, we evaluated treatment with multilineage-differentiating stress-enduring (Muse) cells, endogenous non- tumorigenic pluripotent-like stem cells, as carriers of the HSVtk gene. HSVtk gene-transduced human Muse cells (Muse-tk cells) showed a potent in vivo bystander effect and migratory activity toward glioma cells. Intracranial U87 gliomas in nude mouse brains injected intratumorally with Muse-tk cells followed by intraperitoneal GCV administration were significantly reduced in size within 2 weeks. These findings suggest that intratumoral Muse-tk cell injection followed by systemic GCV administration is safe and effective, and that allogeneic Muse-tk cell-medicated suicide gene therapy for malignant glioma is clinically feasible.
|
